
Glaukos states that the iStent inject offers “proven efficacy and meaningful results with a safety and postoperative care profile similar to cataract surgery”.
It delivers two preloaded stents with a single entry, creating two patent bypass pathways through the trabecular meshwork – the main source of resistance for aqueous outflow – resulting in multidirectional flow through Schlemm’s canal. The iStent inject is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate POAG currently treated with ocular hypotensive medication. It is micro-invasive, astigmatically neutral, and can be implanted with or without cataract surgery.
Contact: www.glaukos.com